Busulfan (Bu) is used as a myeloablative agent in conditioning regimens before allogeneic hematopoietic cell transplantation (allo-HCT). In line with strategies explored in adults, patient outcomes may be optimized by replacing cyclophosphamide (Cy) with or without melphalan (Mel) with fludarabine (Flu). We compared outcomes in 2 consecutive cohorts of HCT recipients with a nonmalignant HCT indication, a myeloid malignancy, or a lymphoid malignancy with a contraindication for total body irradiation (TBI). Between 2009 and 2012, 64 children received Flu þ Bu at a target dose of 80-95 mg$h/L, and between 2005 and 2008, 50 children received Bu targeted to 74-80 mg$h/L þ Cy. In the latter group, Mel was added for patients with myeloid malignancy (n ¼ 12). Possible confounding effects of calendar time were studied in 69 patients receiving a myeloablative dose of TBI between 2005 and 2012. Estimated 2-year survival and event-free survival were 82% and 78%, respectively, in the FluBu arm and 78% and 72%, respectively, in the BuCy (Mel) arm (P ¼ not significant). Compared with the BuCy (Mel) arm, less toxicity was noted in the FluBu arm, with lower rates of acute (noninfectious) lung injury (16% versus 36%; P ¼ .007), veno-occlusive disease (3% versus 28%; P ¼ .003), chronic graft-versus-host disease (9% versus 26%; P ¼ .047), adenovirus infection (3% versus 32%; P ¼ .001), and human herpesvirus 6 infection reactivation (21% versus 44%; P ¼ .005). Furthermore, the median duration of neutropenia was shorter in the FluBu arm (11 days versus 22 days; P < .001), and the patients in this arm required fewer transfusions. Our data indicate that Flu (160 mg/m 2 ) with targeted myeloablative Bu (90 mg$h/L) is less toxic than and equally effective as BuCy (Mel) in patients with similar indications for allo-HCT.
INTRODUCTION
Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for a variety of diseases; however, its use is limited by the risk of graft failure, relapse of malignant disease, transplantation-related complications/ mortality, and late effects. Busulfan (Bu) is the backbone of most chemotherapy-based conditioning regimens, and previous studies have shown a wide variability among children's responses to Bu-based conditioning before allo-HCT [1] [2] [3] [4] [5] . In a previous study, our group demonstrated that a first step in optimizing a conditioning regimen is to target i.v. Bu to an optimal exposure of 78 mg$h/L (AE5 mg$h/L) in combination with cyclophosphamide (Cy) [6] .
Even with individualization of the Bu dose, the toxicity (early and late) of the conditioning regimen remains a major concern. In line with strategies explored in adult transplantation, the next step in further optimizing the pediatric conditioning regimen may be to replace the alkylating agent Cy with the nucleoside analog fludarabine (Flu) as an immunosuppressive agent in the conditioning regimen. Because both Bu and Cy use glutathione S-transferase (GST) in drug metabolism, a combination of these drugs results in GST depletion, thereby increasing the risk of toxicity, whereas Flu does not cause GST depletion [7, 8] . In addition, the FluBu combination may act synergistically on apoptosis of target cells [9] .
Most clinical studies in adult patients using this combination have shown promising results. Compared with BuCy, FluBu has been associated with reduced toxicity (ie, lower rates of veno-occlusive disease [VOD] and graft-versus-host disease [GVHD]) and with improved outcomes [10] [11] [12] [13] . A recent study by Lee et al. [14] did not show a favorable effect of FluBu, however. That study did not use dose targeting of Bu, which might have led to low and variable Bu exposures, possibly accounting for the low donor chimerism reported with the FluBu regimen [14] . Data on the use of FluBu in children are limited [15] [16] [17] [18] . Apart from a phase 1 study reported by Lee et al. [16] , pediatric studies have studied low-dose FluBu in the setting of nonmyeloablative or reduced-intensity conditioning regimens. Little data have been published on the use of high-dose, myeloablative FluBu [19] [20] [21] , and conditioning regimens have not yet been compared. Horn et al. [20] studied high-dose FluBu, but closed the study prematurely owing to a high incidence of graft failure. Switching from antithymocyte globulin (ATG) to alemtuzumab has been shown to increase the rate of engraftment [19] .
In this prospective clinical study, we aimed to reduce the toxicity of the conditioning regimen in pediatric allo-HCT for nonmalignant indications, myeloid malignancy, or lymphoid malignancy with a contraindication for total body irradiation, while maintaining myeloablation and efficacy. We compared the outcomes of 64 pediatric patients included in a prospective study receiving a FluBu conditioning regimen between 2009 and 2012 with a recent historical cohort of 50 pediatric patients receiving BuCy (þmelphalan [Mel] in myeloid malignancies) between 2005 and 2008 in nonmalignant and (mainly) myeloid malignant indications for HCT. The FluBu regimen compared favorably with the BuCy-based regimen, demonstrating similar efficacy with less toxicity.
PATIENTS AND METHODS

Study Design
This prospective study was performed in the pediatric HCT unit of the University Medical Center Utrecht and was approved by the institutional Ethical Committee. Written informed consent was obtained from all participating patients or their legal representatives before allo-HCT. HCT data were collected prospectively in the TRIASUS database [22] , and were captured from the database on June 17, 2013, for this analysis.
Patients were prospectively recruited to 2 consecutive conditioning regimens over an 8-year period. Possible calendar time effects were evaluated using a separate dataset of pediatric patients who received TBI as myeloablative conditioning in our program between 2005 and 2011, assuming a similar therapeutic environment in the calendar time periods for the patients receiving BuCy(Mel) or FluBu and those receiving TBI.
Conditioning Regimens and Patient Inclusion
Patients with a nonmalignant indication (eg, hemoglobinopathies, primary immune deficiencies, metabolic diseases), myeloid malignancy, or lymphoid malignancy with a contraindication for TBI received a Bu-based myeloablative conditioning regimen. TBI was contraindicated in patients with previous craniospinal radiation, poor cardiac function (eg, ejection fraction <30%), or compromised lung function (eg, forced expiratory volume in 1 second <80%). Patients with acute lymphoblastic leukemia (ALL) generally received a TBI-based conditioning regimen.
BuCy(Mel)
Between 2005 and 2009, BuCy(Mel) was the standard conditioning regimen in our center (based on either national or international protocols) for all nonmalignant indications, myeloid malignancies, and lymphoid malignancies with a contraindication for TBI. The initial dose of Bu (Busilvex; Pierre Fabre Medicament, Boulogne, France) was 120 mg/m 2 in patients age >1 year and 80 mg/m 2 in those age <1 year. Bu was administered in a 3-hour infusion once daily, with dose targeting based on therapeutic drug monitoring to a total area under the curve (AUC day0-4 ) of 74-82 mg$h/L (4400-4900 mM$min/day), as described previously [6, 17, 18, [23] [24] [25] . In short, the AUC was based on 3 to 6 blood samples obtained between 5 minutes and 7 hours after the end of Bu infusion on day 1, using a single-compartment model with linear pharmacokinetics established by Cremers and coworkers [26] [27] [28] . Empirical Bayesian pharmacokinetic parameter estimates (ie, clearance and volume of distribution) were estimated using the MwPharm pharmacokinetic software package [29] . The Bu dose was adjusted only when the AUC differed by >10% from the target AUC. Evaluation of the AUC after dose adjustment was performed on the next day and at day þ4. All values were used to calculate the total Bu exposure.
Cy was dosed either 60 mg/kg for 2 days in patients with malignant disease or 50 mg/kg for 4 days in those with nonmalignant disease. Cy was administered at least 24 hours after Bu. Mel was added in patients with myeloid malignancy (ie, myelodysplastic syndrome [MDS] or acute myelogenous leukemia [AML]) and in those with infant ALL. Melphalan was dosed at 140 mg/m 2 once daily after 2 days of Cy therapy. Serotherapy with ATG (Thymoglobulin; Sanofi, Cambridge, MA, USA) 10 mg/kg was administered to all recipients of an unrelated donor graft over 4 days (day À5 to day À2).
FluBu
Patients were included between 2009 and 2012. Flu (Fludara; Sanofi) 40 mg/m 2 was given 1 hour before a once-daily 3-hour infusion of Bu. Starting in 2010, the Bu dose was adjusted to a body weightedependent dosing regimen described by Bartelink et al. [30] . Bu dose targeting was based on therapeutic drug monitoring to an AUC day0-4 of 80-95 mg$h/L (w5400 mM$min/day). Based on reports in adult transplantation, a higher target exposure of Bu was chosen when used in combination with Flu [10, [31] [32] [33] . Serotherapy with ATG 10 mg/kg was administered to unrelated donor graft recipients from day À5 to day À2 and to cord blood recipients from day À8 to day À5. It was anticipated that the earlier administration of ATG in the cord blood recipients would shorten the period of profound T cell depletion, owing to less in vivo T cell depletion.
TBI
Patients received a cumulative TBI dose of 12 Gy (6 Â 2 Gy). These patients were included as the TBI cohort only between 2005 and 2011, because after 2011, the Dutch national conditioning regimen for patients with ALL was changed to a TBI-free regimen containing clofarabine (CloFluBu). These patients were not included in the FluBu cohort. The patients who received TBI were included solely to study possible calendar time effects and had a similar therapeutic environment as the patients receiving BuCy(Mel) or FluBu in the time periods studied.
Supportive Care
GVHD prophylaxis, consisting of cyclosporine A (trough level, 200-250 mg/L) in all patients, remained the same throughout the study period. In recipients of an unrelated bone marrow transplant, methotrexate was added on days þ1, þ3, and þ6 after HCT, and in unrelated cord blood recipients, prednisolone was added up to day þ28 after HCT. Patients included between 2007 and 2009 who received BuCy(Mel) (n ¼ 6) also received defibrotide as VOD prophylaxis as part of a trial [34] . VOD was treated with defibrotide 25 mg/kg/day, given in 4 divided doses. Antimicrobial prophylaxis was standard for all patients. Ciprofloxacin was given starting at the initiation of conditioning and continuing until neutropenia resolved. Pneumocystis carinii pneumonia prophylaxis was started once neutropenia was resolved with co-trimoxazole 30 mg/kg (maximum dose, 960 mg) 3 times per week until a CD4 þ cell count >200/mL was achieved. Patients who were herpes simplex virus seropositive received 500 mg/m 2 (val)acyclovir until day þ28 or until a CD4 þ cell count >200/mL was achieved. Standard antifungal prophylaxis consisted of fluconazole administered from the start of conditioning up to the resolution of neutropenia (neutrophils >500/L for 3 days). From 2008 onward, patients at high risk for fungal infections were given voriconazole as prophylaxis [35] .
Empirical antifungal therapy with voriconazole (trough level targeted to 2-5 mg/L) was initiated in patients with unexplained fever with negative bacterial cultures during neutropenia persisting for longer than 72 hours. In the event of evidence suggesting fungal infection other than with Aspergillus, or invasive yeast infection, liposomal amphotericin-B (AmBisome) was given.
Primary and Secondary Endpoints and Definitions
Primary study endpoints were overall survival (OS), event-free survival (EFS; relapse-free survival in malignant diseases), relapse, and nonrelapse mortality (NRM). OS was defined as the time from transplantation to death; EFS, as survival from transplantation to last contact, autologous reconstitution (defined as documented <10% donor-derived engraftment), or graft failure (defined as a lack of neutrophil recovery or transient engraftment of donor cells after transplantation and/or a requirement for a second transplantation), with relapse and death considered events. NRM was defined as the time from transplantation to death unrelated to underlying disease. All surviving patients were censored at date of last contact.
Secondary endpoints were acute GVHD (aGVHD), diagnosed and graded according to the scheme of Glucksberg et al. [36] ; chronic GVHD (cGVHD); VOD, according to Bearman et al. [37] ; acute noninfectious lung injury (ie, idiopathic pneumonia syndrome [IPS]); and viral reactivation. IPS was defined as the presence of acute bilateral pulmonary infiltrates with cough, dyspnea, and hypoxemia in the absence of infection. Viral reactivation was defined as a viral load >1000 cp/mL: adenovirus, human herpesvirus 6 [HHV6], cytomegalovirus [CMV], and Epstein-Barr virus [EBV]. Viral load was checked weekly up to 4 months after HCT; in the event of low-level reactivation (>100 cp/mL), levels were checked twice weekly.
Other endpoints were neutrophil engraftment (at day þ60), defined as the first day of achieving a neutrophile count of >0.5*10e9/L for 3 consecutive days, and thrombocyte engraftment (at day þ180), achieving a count of count !50 Â 10 9 /L for 7 consecutive days. In addition, the duration of neutropenia, defined as days of a neutrophil count <0.5 Â 10 9 /L between the time of HCT and neutrophil engraftment, was recorded. In addition, the number of erythrocyte and thrombocyte transfusions was noted. Chimerism of >95% was considered full donor chimerism. Donor chimerism of >10% and <95% was considered mixed.
Statistical Analysis
The duration of follow-up was defined as the time to the last assessment for surviving patients or death. To analyze risk factors for outcomes, we considered patient-related factors (eg, age at date of transplantation, sex, treatment-related mortality [TRM] risk), disease (ie, malignant or nonmalignant disease), and donor (ie, source, donor relationship, and HLA disparity). The association between these factors and primary and secondary endpoints were analyzed using Cox proportional hazards regression models, with a P value <.10 on univariate analysis and <.05 on multivariate analysis considered to indicate significance. For visualization, outcome probabilities were calculated using the Kaplan-Meier method. Cumulative incidence estimates were calculated for all secondary outcomes with death as the competing event. Given that the addition of Mel to the conditioning regimen may be the primary cause of toxicity, we also assessed the association between the 2 conditioning regimens without patients with a myeloid malignancy (and infant ALL) in both cohorts, because in the BuCy cohort these patients would have received Mel.
Propensity score adjustment was performed to adjust for possible cohort selection of receiving the FluBu or BuCy(Mel) regimen. These scores were obtained using logistic regression in SPSS [38] , including the covariates stem cell source, HLA matching, indication for HCT, and risk of TRM. Calculated propensity scores were included in multivariate analysis for the primary and toxicity endpoints to adjust for comparability. Calendar time effects in primary and secondary outcome parameters were assessed in a separate analysis by comparing patients who received TBI between 2005 and 2009 and those who did so between 2009 and 2011. Statistical analyses were performed using SPSS version 20.0 (IBM, Armonk, NY).
RESULTS
Patient Characteristics
Between 2005 and 2012, 64 patients received FluBu, 50 received BuCy(Mel), and 69 received TBI conditioning before HCT. Patient age ranged from 2 months to 19 years. The patients in the BuCy(Mel) and FluBu cohorts were comparable in terms of age and indication for HCT ( Table 1 ). The FluBu cohort included more male patients and demonstrated a trend toward greater use of umbilical cord blood (P ¼ .076) as a donor source. Because the FluBu cohort was treated in the more recent period, the duration of follow-up was shorter in this cohort. Furthermore, Bu exposure was higher in the FluBu cohort, given the higher target exposure in this conditioning regimen.
OS and EFS
Two-year estimated OS and EFS were 82% and 78%, respectively, for the FluBu cohort and 78% and 72%, respectively, for the BuCy(Mel) cohort (P ¼ not significant) ( Figure 1A and B ). The number of relapses in patients with malignant disease was not significantly different between the 2 cohorts (P ¼ .361) ( Figure 1C ). Moreover, NRM in all patients did not differ between the 2 cohorts (P ¼ .57). Results of the univariate analysis are presented in the Appendix. Table 2 presents the significant multivariate predictors of OS and EFS, as well of the various toxicity endpoints.
After adjustment for differences in baseline characteristics between the treatment cohorts, anticipated TRM risk (based on European Group for Blood and Marrow Transplantation comorbidity risk score [39, 40] ) and diagnosis remained significant independent predictors of long-term OS and EFS. After excluding myeloid malignancies and infant ALL (ie, the diseases with an indication for Mel), the 2-year estimated OS and EFS were 91% and 89%, respectively, for the FluBu cohort and 71% and 66%, respectively, for the BuCy cohort (P ¼ .059 and .036, respectively; Appendix, bottom row).
Secondary Endpoints
Cumulative incidence curves for the secondary endpoints are shown in Figure 2 . In univariate analysis, the FluBu conditioning regimen predicted a lower risk of VOD, acute lung toxicity, and cGVHD, as shown in the Appendix. Table 3 lists the significant multivariate predictors of the secondary endpoints. After adjustment for differences in baseline characteristics, FluBu and nonmalignant disease were associated with a lower risk of acute lung toxicity, VOD, and cGVHD. There was no impact of the conditioning regimen on the endpoint aGVHD (P ¼ .886). The FluBu conditioning regimen was the sole predictor of a lower risk of viral reactivation (HHV6 and adenovirus), as shown in Figure 3 and Table 2 . The incidence of CMV and EBV reactivation was not significantly different between the 2 cohorts (P ¼ .363 and .155, respectively). All patients in the BuCy(Mel) and FluBu cohorts had full donor chimerism at day þ60 as well as at the latest follow-up time point. After excluding myeloid malignancies (AML, MDS, and juvenile monomyocytic leukemia) and infant ALL (indication for Mel), the association between the conditioning regimen and the secondary endpoints remained the same in the 2 cohorts (Appendix, bottom row), with lower toxicity in the FluBu cohort.
Other Endpoints
The probability of neutrophil engraftment at day 60 was 98% in both cohorts. Probability of thrombocyte engraftment (platelets >50$10 9 /L) at day þ180 was higher in the FluBu cohort (93% versus 82%; P ¼ .005). In addition, time to thrombocyte engraftment and duration of neutropenia were significantly longer in the BuCy(Mel) cohort compared with the FluBu cohort (Table 3 ). In addition, the patients treated with FluBu required significantly fewer erythrocyte transfusions (median, 2 versus 5; P ¼ .009) and thrombocyte transfusions (median, 5 versus 12; P ¼ .001) after HCT.
Calendar Time Effects in the TBI Cohort
A myeloablative dose of TBI was used for conditioning in patients with ALL (n ¼ 61; 88%), AML (n ¼ 3; 4%), and non-Hodgkin lymphoma (n ¼ 5; 8%) undergoing allo-HCT. Patient characteristics are summarized in Table 4 . The TBI cohort demonstrated no significant calendar time effect for the primary endpoints OS and EFS or for any the secondary endpoints (Table 4 ). In addition, there was no overall trend toward an effect on the incidence of toxicity.
DISCUSSION
This study shows a favorable effect of FluBu compared with BuCy (Mel) on the outcomes of allo-HCT in a variety of pediatric malignant and nonmalignant diseases. Despite the greater Bu exposure in the FluBu cohort compared with the BuCy cohort, the FluBu regimen was less toxic and associated with a shorter neutropenic period and fewer blood transfusions, while maintaining equivalent efficacy. These results are in line with observations in adults, which show a low toxicity profile in favor of the FluBu cohort with equivalent or even improved efficacy [10, 11, 13, 33, 41] ; however, Horwitz et al. [42] prematurely closed a study of dual cord blood transplants using FluBu owing to a high number of graft failures, and Lee et al. [14] reported lower donor chimerism in patients treated with Flu combined with untargeted Bu compared with BuCy(Mel)-treated patients (44% versus 97.2%; P < .001).
The low engraftment in these 2 studies could be related to the lack of serotherapy (ATG or Campath) in recipients of unrelated donor transplants owing to lower target AUC (median, 69.3 mg$h/L in the Horwitz et al. study [42] ) or an untargeted, lower, and variable Bu exposure (in the Lee et al. study [14] ). A pediatric study by Horn et al. [20] also found a high incidence of graft failure, possibly related to the low target exposure of Bu. Thus, we propose maintaining therapeutic drug monitoring and targeting to a higher Bu exposure of 80 to 95 mg$h/L when using FluBu in children. This high target AUC is similar to that used for adults at M.D. Anderson Cancer Center [32, 43] . Although the follow-up period of in our FluBu cohort may be short to allow optimal assessment of efficacy, the high rate of donor engraftment is promising across a wide range of diagnoses, including metabolic disorders, where donor chimerism can be difficult to achieve. This is the first pediatric study to use myeloablative Bu exposure and to compare outcomes after FluBu with BuCy(Mel) as a conditioning regimen.
The optimal approach for comparing different conditioning regimens is to perform a prospective randomized trial as comparisons of single-arm, consecutive trials may suffer from confounding effects of (un)known factors, including improved supportive care, introduction of new antifungals, change in the timing of ATG administration, and increased experience of the nursing and medical staff. The use of defined clinical endpoints and prospective inclusion diminished assessor bias as much as possible. In this study, possible confounding effects of calendar time were assessed by exploiting the data from the TBI cohort, a program that remained unchanged from 2005 to 2011. The relatively small size of the TBI cohort (n ¼ 68) might have limited the study's power to fully address this limitation, however. Because of the relatively small sample size, it was not possible to fully assess differences in outcomes among various subgroups within the malignant and nonmalignant groups. Furthermore, propensity scores were used to adjust for possible group selection of the use of a FluBu or BuCy(Mel) conditioning regimen. Although this study may have some limitations, these cannot account for the promising results of less VOD, less chronic GVHD, shorter duration of neutropenia, and fewer transfusions seen with the use of FluBu as myeloablative conditioning, despite the higher Bu exposure targeted in this cohort.
The pattern of toxicity (lung, hepatic, and cGVHD) and more rapid thrombocyte engraftment with FluBu suggests a reduction in endothelial damage [44] . The low risk of FluBu toxicity is most likely related to the nonoverlapping organ toxicity of the 2 drugs, with Flu not dependent on hepatic glutathione stores for detoxification. By decreasing the levels of glutathione, toxic Cy metabolites and Bu may have a synergetic toxic effect [7, 8] . This effect is more pronounced when
BuCy is combined with Mel [6, 45] . Of the 12 patients who received BuCyMel, 6 who were enrolled between 2007 and 2009 received defibrotide as prophylaxis. Defibrotide might have decreased the incidence of VOD in these patients, as described by Corbacioglu et al. [34] . Thus, without the use of defibrotide, the cumulative incidence of VOD in the BuCy(Mel) cohort would have been even greater and the difference between the cohorts larger. The subgroup analysis (excluding patients with myeloid malignancy from both cohorts, who would have received Mel in the BuCy conditioning) demonstrated that the lower toxicity profile of FluBu was not solely related to dropping Mel from the conditioning.
Changing the conditioning regimen from BuCy(Mel) to FluBu in patients with similar indications for HCT significantly reduced the risk of HHV6 and adenovirus infection and shortened the neutropenic period in these pediatric patients, effects that have not been reported previously to our knowledge. Our group previously reported that HHV6 reactivation is significantly associated with serious transplantation-related morbidity and mortality [46, 47] . Thus, reducing the incidence of HHV6 reactivation is critical to optimizing HCT outcomes. The earlier administration of ATG (from day À8 to day À5) in cord blood recipients might have contributed to the lower incidence of these viral reactivations, possibly providing less in vivo T cell depletion and subsequently resulting in better T cell reconstitution.
In contrast to the unchanged incidence of CMV and EBV infections seen in the present study, some previous studies reported that Flu-containing conditioning regimens were associated with higher incidences of opportunistic infections, such as CMV and EBV, after transplantation because of the immunosuppressive effect of Flu [48, 49] . This effect of low rates of viral reactivation after cord blood transplantation was previously described by Chiesa et al. [50] in a series of pediatric cord blood recipients without ATG in the conditioning regimen. Shortening the period of chemotherapy administration from 7 to 9 days (days À9 to À2) in the BuCy(Mel) cohort to 4 days (days À5 to À2) in the FluBu cohort, the low toxicity profile of FluBu might have resulted in the shorter neutropenic period and rapid cell engraftment in the FluBu cohort. Now that we and others have shown that FluBu is a safe and a low-toxicity regimen in pediatric and adult patients, the next step may be a randomized controlled trial to confirm our results. A randomized trial is underway in a more focused disease population of juvenile monomyocytic leukemia in the Children's Oncology Group (ClinicalTrials.gov: NCT01824693). Furthermore, future strategies may focus on the use of FluBu as a conditioning platform for HCT in all diseases and for providing better disease control in malignant diseases. Dose targeting of Bu is critical to improve outcomes of HCT [32, [51] [52] [53] [54] . Lee et al. [14] showed that combining Flu with untargeted Bu may result in low donor chimerism. The optimal dosing of and exposure to Bu in children, defined using the BuCy(Mel) regimen [6, 30, 55, 56] , were increased in this study when Bu was used in combination with Flu. In this new FluBu regimen, further fine-tuning of the Bu dose is needed. For instance, in nonmalignant diseases, exposure deescalation can be used to determine the lowest acceptable exposure not be associated with graft failure. More recent studies suggest that optimal dosing of Flu may be essential as well. Long-Boyle et al. [57] reported a correlation between Flu concentrations and TRM, whereas a saturation of intracellular uptake of Flu may reduce efficacy of higher Flu dosing (personal communication, J. Long-Boyle, August 2013). Compared with the Flu dose of 160 mg/m 2 given over 4 days in the present study, some previous adult studies used higher cumulative Flu doses, up to 250 mg/m 2 administered over 4 or more consecutive days [12, 32, 33] . Lee et al. [14] showed that in children, Flu 250 mg/m 2 and Bu with an AUC day0-4 of 72.5-80 mg$h/L are associated with a high incidence of toxicity, suggesting that increased Flu exposure may be the cause of this toxicity, given that the Bu exposure was lower than that in the present study. A reduction of the Bu target AUC to 72-76 mg$h/L decreased toxicity, but the incidence of graft failure remained significant [16] . In contrast, we found a low toxicity rate and excellent engraftment with a regimen of Bu targeted to 80-95 mg$h/L combined with Flu 160 mg/m 2 . Pre-HCT intervention to improve disease control (eg, by adding a third nonalkylating agent, such as gemcitabine or clofarabine) may result in synergistic cytotoxicity, as described previously [58, 59] . Clinically, BuFlu þ Clo was proven safe in 51 very-high-risk patients with AML/MDS (mainly adults) [60] . Other strategies may include adding low-dose TBI, as explored by Russell and coworkers [61, 62] ; however, this might not be a good option in pediatric patients, given the association between TBI and severe late effects. Furthermore, post-HCT interventions with either novel agents (eg, sirolimus, histone deacetylase inhibitors, tyrosine kinase inhibitors) or immune interventions (eg, cellular), on a FluBu backbone may be considered [63] [64] [65] [66] [67] . Further individualization of the target exposure of Bu, Flu, or other drugs in the conditioning regimen and improved disease control by disease-specific additions also may contribute to safer and more effective allo-HCT.
In conclusion, we have shown that Flu 160 mg/m 2 combined with i.v. Bu targeted to a myeloablative exposure (80-95 mg$h/L) has a positive impact on post-HCT safety, while maintaining efficacy in pediatric malignant and nonmalignant HCT indications. This favorable toxicity profile of this FluBu regimen merit its consideration as conditioning platform for HCT in all indications in future studies. In addition to a randomized controlled trial to confirm our results, further studies are warranted to fine-tune such a FluBu platform.
